Clinical trial

Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

NCT00097500

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-09-01

PhasePHASE3

Study timeline

Study start (unknown)2004-09-01Date precision: month

Registry last updated2015-04-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetes Mellitusunresolved

Interventions

exenatideDRUG · verified · RxNorm: exenatide

Insulin glargineDRUG · verified · RxNorm: insulin glargine

MetforminDRUG · verified · RxNorm: metformin

Sponsors & collaborators

AstraZenecalead sponsor

Eli Lilly and Companycollaborator

Mapped research locations

AmsterdamNetherlands1 GothenburgSweden1 HelsinkiFinland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00097500 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.